Cite
Velaparthi U, Darne CP, Warrier J, et al. Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent. ACS Med Chem Lett. 2020;11(2):172-178doi: 10.1021/acsmedchemlett.9b00552.
Velaparthi, U., Darne, C. P., Warrier, J., Liu, P., Rahaman, H., Augustine-Rauch, K., Parrish, K., Yang, Z., Swanson, J., Brown, J., Dhar, G., Anandam, A., Holenarsipur, V. K., Palanisamy, K., Wautlet, B. S., Fereshteh, M. P., Lippy, J., Tebben, A. J., Sheriff, S., Ruzanov, M., Yan, C., Gupta, A., Gupta, A. K., Vetrichelvan, M., Mathur, A., Gelman, M., Singh, R., Kinsella, T., Murtaza, A., Fargnoli, J., Vite, G., & Borzilleri, R. M. (2020). Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent. ACS medicinal chemistry letters, 11(2), 172-178. https://doi.org/10.1021/acsmedchemlett.9b00552
Velaparthi, Upender, et al. "Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent." ACS medicinal chemistry letters vol. 11,2 (2020): 172-178. doi: https://doi.org/10.1021/acsmedchemlett.9b00552
Velaparthi U, Darne CP, Warrier J, Liu P, Rahaman H, Augustine-Rauch K, Parrish K, Yang Z, Swanson J, Brown J, Dhar G, Anandam A, Holenarsipur VK, Palanisamy K, Wautlet BS, Fereshteh MP, Lippy J, Tebben AJ, Sheriff S, Ruzanov M, Yan C, Gupta A, Gupta AK, Vetrichelvan M, Mathur A, Gelman M, Singh R, Kinsella T, Murtaza A, Fargnoli J, Vite G, Borzilleri RM. Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent. ACS Med Chem Lett. 2020 Jan 28;11(2):172-178. doi: 10.1021/acsmedchemlett.9b00552. eCollection 2020 Feb 13. PMID: 32071685; PMCID: PMC7025382.
Copy
Download .nbib